Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envista HoldingsMEX:NVST 79 Debt-to-EBITDA is 4.06 as of Mar. 2026, which is 7% above its 10-year median of 3.79. GuruFocus rates MEX:NVST with a GF Score™ of 79/100 and a GF Value™ of MXN323.50. The stock has 5 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Envista Holdings ranks worse than 76.76% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Envista Holdings's Debt-to-EBITDA or its related term are showing as below:
MEX:NVST'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.75 Med: 3.79 Max: 9.67
Current: 4.1
During the past 10 years, the highest Debt-to-EBITDA Ratio of Envista Holdings was 9.67. The lowest was -1.75. And the median was 3.79.
MEX:NVST's Debt-to-EBITDA is ranked worse than 76.76% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs MEX:NVST: 4.10
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Envista Holdings Debt-to-EBITDA Related Terms
Envista Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Envista Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NVST vs MMSI, ICUI, MMED: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Envista Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envista Holdings Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envista Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Envista Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Envista Holdings (MEX:NVST) has a Debt-to-EBITDA of 4.06 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Envista Holdings. This is near median its historical median of 3.79. According to the industry distribution chart, Envista Holdings ranks #360 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 76.8%.
Is Envista Holdings' Debt-to-EBITDA too high?
Envista Holdings' current Debt-to-EBITDA of 4.06 is near median its 10-year median of 3.79. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. Envista Holdings' value of 4.06 is 153.8% above this industry median. Based on the distribution chart, Envista Holdings ranks #360 out of 469 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Envista Holdings has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Envista Holdings' Debt-to-EBITDA compare to MMSI and ICUI?
According to the Medical Devices & Instruments industry distribution chart, Envista Holdings ranks #360 out of 469 companies for Debt-to-EBITDA. This places Envista Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. Envista Holdings' value of 4.06 is 153.8% above this benchmark. While the company's 10-year median is 3.79 vs. the industry median of 1.60, Envista Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Envista Holdings's current Debt-to-EBITDA of 4.06 is 153.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Envista Holdings. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envista Holdings's current Debt-to-EBITDA is 4.06, which is near median its own 10-year median of 3.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envista Holdings stock overvalued right now?
Envista Holdings (MEX:NVST) has a current Debt-to-EBITDA of 4.06. The stock's GF Value™ is MXN323.50, compared to a current price of MXN370.00 — trading 14.4% above its estimated fair value. The current Debt-to-EBITDA is 4.06, which is near median its 10-year median of 3.79 and 153.8% above the Medical Devices & Instruments industry median of 1.60. Envista Holdings' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Envista Holdings (MEX:NVST), the current Debt-to-EBITDA is 4.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envista Holdings (MEX:NVST) Overvalued in 2026?
Based on GuruFocus' analysis, Envista Holdings stock appears to be overvalued.
The current stock price of MXN370.00 is trading 14.4% above its estimated GF Value™ of MXN323.50.
Key valuation signals for MEX:NVST:
Debt-to-EBITDA: 4.06 (near median its 10-year median of 3.79)
GF Value™: MXN323.50 vs. price of MXN370.00 (14.4% above fair value)
Industry Position: 153.8% above the Medical Devices & Instruments median (#360 of 469)
No single metric tells the full story. See the MEX:NVST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
79GF Score
Get the complete analysis for MEX:NVST
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVST has been successfully added to your 
